|
|
|
| Expression Level and Clinical Significance of Anti-mullerian Hormone in Serum of Patients with Polycystic Ovary Syndrome |
| GONG Qin, GUO Wei |
| Department of Obstetrics and Gynecology,Chang'an Hospital,Xi'an Shaanxi 710016 |
|
|
|
|
Abstract 【Objective】To investigate the expression level and clinical significance of anti-mullerian hormone (AMH) in serum of patients with polycystic ovary syndrome (PCOS). 【Methods】Ninety-one patients with PCOS were selected from January 2019 to January 2021 in our hospital as the observation group,and 90 healthy volunteers were selected as the control group. Serum AMH levels were detected by chemiluminescence (DXI800,Beckman) to compare the levels of serum AMH in patients with polycystic ovary syndrome and healthy women,which explored diagnostic value for polycystic ovary syndrome.【Results】 Serum level of AMH in patients with polycystic ovary syndrome was higher than that in the control group (P<0.05). Univariate analysis showed that age ≥35 years old,obesity,history of induced abortion,rare ovulation and serum AMH level ≥ 4.5 ng/mL was associated with polycystic ovary syndrome (P<0.05). Multivariate logistic regression analysis showed that age ≥ 35 years old,obesity,history of induced abortion,rare ovulation and serum ≥4.5 ng/mL was the risk factor of polycystic ovary syndrome (P<0.05). The sensitivity and specificity of serum AMH level in the diagnosis of polycystic ovary syndrome were 78.9% and 90.9%,respectively. The area under the working characteristic curve (AUC) was 0.855 and the 95%CI was 0.769~0.919. 【Conclusion】Serum AMH level in patients with polycystic ovary syndrome is abnormally high. Our results show that age≥ 35 years old ,obesity,history of induced abortion,infrequent ovulation,and serum AMH levels ≥ 4.5 ng/mL are all risk factors for the occurrence of PCOS. The level of serum AMH has a high value in the diagnosis of polycystic ovary syndrome.
|
|
Received: 22 April 2022
|
|
|
|
|
|
[1] 董飞天,李瑞宁. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清HE4、hK10、CA125水平的影响[J].医学临床研究,2022,39(7):1054-1057.
[2] LINDBERG M,BORGSTRØM HAGER H,BROKNER M. Week-to-week biological variation of methylmalonic acid and homocysteine in healthy women [J].Scand J Clin Lab Invest,2019,79(4):247-250.
[3] LIU R B,LIU Y,LV L Q,et al. Effects of metformin treatment on soluble amh receptor levels in women with polycystic ovary syndrome [J].Curr Med Sci,2019,39(4):609-614.
[4] BOSCH E,DE VOS M,HUMAIDAN P. The future of cryopreservation in assisted reproductive technologies [J].Front Endocrinol (Lausanne),2020,20(14):67.
[5] OZZOLA G. Anti-Müllerian hormone:A brief review of the literature[J].Clin Ter,2019,68(1):14-22.
[6] 宋颖,李蓉. 多囊卵巢综合征中国诊疗指南解读[J].实用妇产科杂志,2019,34(10):22-26.
[7] UMAYAL B,JAYAKODY S N,CHANDRASEKHARAN N V,et al. Polycystic ovary syndrome and AMH - A Sri Lankan study [J].J Postgrad Med,2019,65(1):18-23.
[8] 刘艳红.Kiss1和GPR54基因多态性与多囊卵巢综合征相关性分析[J].基因组学与应用生物学,2020,39(3):444-449.
[9] 刘敏,曹琦,钱俏红,等. 葆癸胶囊联合西药对多囊卵巢综合征患者抗苗勒管激素影响的临床观察[J].上海中医药杂志,2018,52(6):40-43.
[10] MERKIN S S,PHY J L,SITES C K,et al. Environmental determinants of polycystic ovary syndrome [J].Fertil Steril,2019,106(1):16-24.
[11] VELL R,ANAND-IVELL R. Insulin-like peptide 3 (INSL3) is a major regulator of female reproductive physiology [J].Hum Reprod Update,2019,24(6):639-651.
[12] COPP T,HERSCH J,MUSCAT D M,et al. The benefits and harms of receiving a polycystic ovary syndrome diagnosis:a qualitative study of women's experiences [J].Hum Reprod Open,2019,31(4):26.
[13] ÇELIK H G,ÇELIK E,POLAT I. Evaluation of biochemical hyperandrogenism in adolescent girls with menstrual irregularities[J].J Med Biochem,2019,37(1):7-11.
[14] GEORGOPOULOS N A.Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS) [J].Hormones (Athens),2019,13(2):213-221. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(2): 278-280. |
|
|
|
|
2023, Vol. 40 
